Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer

Bikram Shrestha, Yifei Sun, Farzana Faisal, Victoria Kim, Kevin Soares, Alex Blair, Joseph M. Herman, Amol Narang, Avani S. Dholakia, Lauren Rosati, Amy Hacker-Prietz, Linda Chen, Daniel Laheru, Ana De Jesus-Acosta, Dung Le, Ross C Donehower, Nilofer Azad, Luis A. Diaz, Adrian Murphy, Valerie Lee & 11 others Elliot K Fishman, Ralph H Hruban, Tingbo Liang, John L Cameron, Martin A Makary, Matthew J Weiss, Nita Ahuja, Jin He, Christopher Wolfgang, Chiung Yu Huang, Lei Zheng

Research output: Contribution to journalArticle

Abstract

The use of neoadjuvant chemotherapy or radiation for borderline resectable pancreatic adenocarcinoma (BL-PDAC) is increasing. However, the impact of neoadjuvant chemotherapy and radiation therapy on the outcome of BL-PDAC remains to be elucidated. We performed a retrospective analysis of 93 consecutive patients who were diagnosed with BL-PDAC and primarily followed at Johns Hopkins Hospital between February 2007 and December 2012. Among 93 patients, 62% received upfront neoadjuvant chemotherapy followed by chemoradiation, whereas 20% received neoadjuvant chemoradiation alone and 15% neoadjuvant chemotherapy alone. Resectability following all neoadjuvant therapy was 44%. Patients who underwent resection with a curative intent had a median overall survival (mOS) of 25.8 months, whereas those who did not undergo surgery had a mOS of 11.9 months. However, resectability and overall survival were not significantly different between the three types of neoadjuvant therapy. Nevertheless, 22% (95% CI, 0.13–0.36) of the 58 patients who received upfront chemotherapy followed by chemoradiation remained alive for a minimum of 48 months compared to none of the 19 patients who received upfront chemoradiation. Among patients who underwent curative surgical resection, 32% (95% CI, 0.19–0.55) of those who received upfront chemotherapy remained disease free at least 48 months following surgical resection, whereas none of the eight patients who received upfront chemoradiation remained disease free beyond 24 months following surgical resection. Neoadjuvant therapy with upfront chemotherapy may result in long-term survival in a subpopulation of patients with BL-PDAC.

Original languageEnglish (US)
Pages (from-to)1552-1562
Number of pages11
JournalCancer Medicine
Volume6
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Pancreatic Neoplasms
Drug Therapy
Neoadjuvant Therapy
Survival
Adenocarcinoma
Radiotherapy
Radiation

Keywords

  • Borderline resectable pancreatic adenocarcinoma
  • chemoradiation
  • neoadjuvant therapy
  • pancreatic cancer
  • resectability

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. / Shrestha, Bikram; Sun, Yifei; Faisal, Farzana; Kim, Victoria; Soares, Kevin; Blair, Alex; Herman, Joseph M.; Narang, Amol; Dholakia, Avani S.; Rosati, Lauren; Hacker-Prietz, Amy; Chen, Linda; Laheru, Daniel; De Jesus-Acosta, Ana; Le, Dung; Donehower, Ross C; Azad, Nilofer; Diaz, Luis A.; Murphy, Adrian; Lee, Valerie; Fishman, Elliot K; Hruban, Ralph H; Liang, Tingbo; Cameron, John L; Makary, Martin A; Weiss, Matthew J; Ahuja, Nita; He, Jin; Wolfgang, Christopher; Huang, Chiung Yu; Zheng, Lei.

In: Cancer Medicine, Vol. 6, No. 7, 01.07.2017, p. 1552-1562.

Research output: Contribution to journalArticle

Shrestha, Bikram ; Sun, Yifei ; Faisal, Farzana ; Kim, Victoria ; Soares, Kevin ; Blair, Alex ; Herman, Joseph M. ; Narang, Amol ; Dholakia, Avani S. ; Rosati, Lauren ; Hacker-Prietz, Amy ; Chen, Linda ; Laheru, Daniel ; De Jesus-Acosta, Ana ; Le, Dung ; Donehower, Ross C ; Azad, Nilofer ; Diaz, Luis A. ; Murphy, Adrian ; Lee, Valerie ; Fishman, Elliot K ; Hruban, Ralph H ; Liang, Tingbo ; Cameron, John L ; Makary, Martin A ; Weiss, Matthew J ; Ahuja, Nita ; He, Jin ; Wolfgang, Christopher ; Huang, Chiung Yu ; Zheng, Lei. / Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. In: Cancer Medicine. 2017 ; Vol. 6, No. 7. pp. 1552-1562.
@article{458076d41a774a25ba21590fb787b4e9,
title = "Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer",
abstract = "The use of neoadjuvant chemotherapy or radiation for borderline resectable pancreatic adenocarcinoma (BL-PDAC) is increasing. However, the impact of neoadjuvant chemotherapy and radiation therapy on the outcome of BL-PDAC remains to be elucidated. We performed a retrospective analysis of 93 consecutive patients who were diagnosed with BL-PDAC and primarily followed at Johns Hopkins Hospital between February 2007 and December 2012. Among 93 patients, 62{\%} received upfront neoadjuvant chemotherapy followed by chemoradiation, whereas 20{\%} received neoadjuvant chemoradiation alone and 15{\%} neoadjuvant chemotherapy alone. Resectability following all neoadjuvant therapy was 44{\%}. Patients who underwent resection with a curative intent had a median overall survival (mOS) of 25.8 months, whereas those who did not undergo surgery had a mOS of 11.9 months. However, resectability and overall survival were not significantly different between the three types of neoadjuvant therapy. Nevertheless, 22{\%} (95{\%} CI, 0.13–0.36) of the 58 patients who received upfront chemotherapy followed by chemoradiation remained alive for a minimum of 48 months compared to none of the 19 patients who received upfront chemoradiation. Among patients who underwent curative surgical resection, 32{\%} (95{\%} CI, 0.19–0.55) of those who received upfront chemotherapy remained disease free at least 48 months following surgical resection, whereas none of the eight patients who received upfront chemoradiation remained disease free beyond 24 months following surgical resection. Neoadjuvant therapy with upfront chemotherapy may result in long-term survival in a subpopulation of patients with BL-PDAC.",
keywords = "Borderline resectable pancreatic adenocarcinoma, chemoradiation, neoadjuvant therapy, pancreatic cancer, resectability",
author = "Bikram Shrestha and Yifei Sun and Farzana Faisal and Victoria Kim and Kevin Soares and Alex Blair and Herman, {Joseph M.} and Amol Narang and Dholakia, {Avani S.} and Lauren Rosati and Amy Hacker-Prietz and Linda Chen and Daniel Laheru and {De Jesus-Acosta}, Ana and Dung Le and Donehower, {Ross C} and Nilofer Azad and Diaz, {Luis A.} and Adrian Murphy and Valerie Lee and Fishman, {Elliot K} and Hruban, {Ralph H} and Tingbo Liang and Cameron, {John L} and Makary, {Martin A} and Weiss, {Matthew J} and Nita Ahuja and Jin He and Christopher Wolfgang and Huang, {Chiung Yu} and Lei Zheng",
year = "2017",
month = "7",
day = "1",
doi = "10.1002/cam4.1104",
language = "English (US)",
volume = "6",
pages = "1552--1562",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "7",

}

TY - JOUR

T1 - Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer

AU - Shrestha, Bikram

AU - Sun, Yifei

AU - Faisal, Farzana

AU - Kim, Victoria

AU - Soares, Kevin

AU - Blair, Alex

AU - Herman, Joseph M.

AU - Narang, Amol

AU - Dholakia, Avani S.

AU - Rosati, Lauren

AU - Hacker-Prietz, Amy

AU - Chen, Linda

AU - Laheru, Daniel

AU - De Jesus-Acosta, Ana

AU - Le, Dung

AU - Donehower, Ross C

AU - Azad, Nilofer

AU - Diaz, Luis A.

AU - Murphy, Adrian

AU - Lee, Valerie

AU - Fishman, Elliot K

AU - Hruban, Ralph H

AU - Liang, Tingbo

AU - Cameron, John L

AU - Makary, Martin A

AU - Weiss, Matthew J

AU - Ahuja, Nita

AU - He, Jin

AU - Wolfgang, Christopher

AU - Huang, Chiung Yu

AU - Zheng, Lei

PY - 2017/7/1

Y1 - 2017/7/1

N2 - The use of neoadjuvant chemotherapy or radiation for borderline resectable pancreatic adenocarcinoma (BL-PDAC) is increasing. However, the impact of neoadjuvant chemotherapy and radiation therapy on the outcome of BL-PDAC remains to be elucidated. We performed a retrospective analysis of 93 consecutive patients who were diagnosed with BL-PDAC and primarily followed at Johns Hopkins Hospital between February 2007 and December 2012. Among 93 patients, 62% received upfront neoadjuvant chemotherapy followed by chemoradiation, whereas 20% received neoadjuvant chemoradiation alone and 15% neoadjuvant chemotherapy alone. Resectability following all neoadjuvant therapy was 44%. Patients who underwent resection with a curative intent had a median overall survival (mOS) of 25.8 months, whereas those who did not undergo surgery had a mOS of 11.9 months. However, resectability and overall survival were not significantly different between the three types of neoadjuvant therapy. Nevertheless, 22% (95% CI, 0.13–0.36) of the 58 patients who received upfront chemotherapy followed by chemoradiation remained alive for a minimum of 48 months compared to none of the 19 patients who received upfront chemoradiation. Among patients who underwent curative surgical resection, 32% (95% CI, 0.19–0.55) of those who received upfront chemotherapy remained disease free at least 48 months following surgical resection, whereas none of the eight patients who received upfront chemoradiation remained disease free beyond 24 months following surgical resection. Neoadjuvant therapy with upfront chemotherapy may result in long-term survival in a subpopulation of patients with BL-PDAC.

AB - The use of neoadjuvant chemotherapy or radiation for borderline resectable pancreatic adenocarcinoma (BL-PDAC) is increasing. However, the impact of neoadjuvant chemotherapy and radiation therapy on the outcome of BL-PDAC remains to be elucidated. We performed a retrospective analysis of 93 consecutive patients who were diagnosed with BL-PDAC and primarily followed at Johns Hopkins Hospital between February 2007 and December 2012. Among 93 patients, 62% received upfront neoadjuvant chemotherapy followed by chemoradiation, whereas 20% received neoadjuvant chemoradiation alone and 15% neoadjuvant chemotherapy alone. Resectability following all neoadjuvant therapy was 44%. Patients who underwent resection with a curative intent had a median overall survival (mOS) of 25.8 months, whereas those who did not undergo surgery had a mOS of 11.9 months. However, resectability and overall survival were not significantly different between the three types of neoadjuvant therapy. Nevertheless, 22% (95% CI, 0.13–0.36) of the 58 patients who received upfront chemotherapy followed by chemoradiation remained alive for a minimum of 48 months compared to none of the 19 patients who received upfront chemoradiation. Among patients who underwent curative surgical resection, 32% (95% CI, 0.19–0.55) of those who received upfront chemotherapy remained disease free at least 48 months following surgical resection, whereas none of the eight patients who received upfront chemoradiation remained disease free beyond 24 months following surgical resection. Neoadjuvant therapy with upfront chemotherapy may result in long-term survival in a subpopulation of patients with BL-PDAC.

KW - Borderline resectable pancreatic adenocarcinoma

KW - chemoradiation

KW - neoadjuvant therapy

KW - pancreatic cancer

KW - resectability

UR - http://www.scopus.com/inward/record.url?scp=85021286831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021286831&partnerID=8YFLogxK

U2 - 10.1002/cam4.1104

DO - 10.1002/cam4.1104

M3 - Article

VL - 6

SP - 1552

EP - 1562

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 7

ER -